Brief: Kala Pharmaceuticals Receives FDA Fast Track Designation For KPI-012
Kala Pharma up as FDA grants fast track tag to eye disease therapy
Brief: Kala Pharmaceuticals Announces Positive Safety Update From Cohort 1 Of Chase Phase 2B Clinical Trial Evaluating Kpi-012 In Patients With PCED
U.S. RESEARCH ROUNDUP-DR Horton, KB Home, Vir Biotechnology
Brief: Kala Pharmaceuticals Inc Files For Mixed Shelf Of Up To $350 Mln - SEC Filing
Brief: Kala Pharmaceuticals Inc Files For Resale Of Up To 5.4 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Brief: Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Kala Pharmaceuticals Inc Files For Common Stock Offering Of Up To $40 Mln
Brief: Kala Pharmaceuticals' Application To Transfer Listing Approved By Nasdaq
Kala soars as FDA accepts application to start eye defect drug trial
Brief: FDA Accepts Kala Pharmaceuticals' IND Application for KPI-012
Brief: Kala Pharmaceuticals Inc - On December 5, Co Received Notice Of Delisting From Nasdaq - Filing
U.S. STOCKS ON THE MOVE-Apple Inc, Expensify Inc, Nexstar Media Group
U.S. STOCKS ON THE MOVE-Novavax, Cerence, Hibbett
U.S. STOCKS ON THE MOVE-Citi Trends, ConocoPhillips, ASP Isotopes
U.S. STOCKS ON THE MOVE-Oil firms, Ulta Beauty, gold miners
Kala Pharma up on submission of application to further eye drug study
Brief: Kala Pharmaceuticals Announces Up To $31 Mln Private Placement Financing
Brief: Kala Pharmaceuticals Submits Investigational New Drug Application For Kpi-012 For Treatment Of Persistent Corneal Epithelial Defect